(0.33%) 5 116.70 points
(0.33%) 38 364 points
(0.36%) 15 986 points
(-0.94%) $83.06
(5.56%) $2.03
(0.35%) $2 355.30
(0.46%) $27.66
(4.03%) $959.30
(-0.25%) $0.932
(-0.41%) $10.98
(-0.58%) $0.796
(1.69%) $93.43
Live Chart Being Loaded With Signals
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States...
Stats | |
---|---|
本日の出来高 | 18 288.00 |
平均出来高 | 129 386 |
時価総額 | 68.19M |
EPS | $0 ( 2024-03-27 ) |
次の収益日 | ( $-0.450 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0300 |
ATR14 | $0.0780 (0.79%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-18 | Smith J. Jefferson | Buy | 31 343 | Restricted Stock Units |
2024-04-18 | Amoroso Michael | Buy | 111 217 | Restricted Stock Units |
2024-04-18 | Scimeca Dario | Buy | 25 277 | Restricted Stock Units |
2024-04-18 | Kelly John Alexander | Buy | 41 705 | Restricted Stock Units |
2024-01-20 | Kelly John Alexander | Buy | 116 690 | Common Stock |
INSIDER POWER |
---|
35.43 |
Last 99 transactions |
Buy: 6 131 576 | Sell: 2 082 385 |
ボリューム 相関
Precision BioSciences Inc 相関
10 最も負の相関 | |
---|---|
MMAC | -0.93 |
OBT | -0.926 |
ZGNX | -0.918 |
MPRA | -0.903 |
ADMS | -0.901 |
ARNA | -0.898 |
NETE | -0.898 |
NCAC | -0.896 |
NSIT | -0.895 |
PLPC | -0.894 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Precision BioSciences Inc 相関 - 通貨/商品
Precision BioSciences Inc 財務諸表
Annual | 2023 |
収益: | $48.73M |
総利益: | $40.47M (83.06 %) |
EPS: | $-18.16 |
FY | 2023 |
収益: | $48.73M |
総利益: | $40.47M (83.06 %) |
EPS: | $-18.16 |
FY | 2022 |
収益: | $25.10M |
総利益: | $16.09M (64.12 %) |
EPS: | $-41.95 |
FY | 2021 |
収益: | $115.53M |
総利益: | $0.00 (0.00 %) |
EPS: | $-0.520 |
Financial Reports:
No articles found.
Precision BioSciences Inc
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。